SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-027969
Filing Date
2023-04-06
Accepted
2023-04-06 16:05:10
Documents
13
Period of Report
2023-03-31
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea176605-8k_tffpharma.htm   iXBRL 8-K 31059
2 FIRST AMENDED AND RESTATED BYLAWS OF TFF PHARMACEUTICALS, INC. ea176605ex3-1_tffpharma.htm EX-3.1 156583
  Complete submission text file 0001213900-23-027969.txt   396495

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tffp-20230331.xsd EX-101.SCH 3230
4 XBRL LABEL FILE tffp-20230331_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tffp-20230331_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea176605-8k_tffpharma_htm.xml XML 3823
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 23806178
SIC: 2834 Pharmaceutical Preparations